Weighted-Average Shares Outstanding (Diluted): The number of shares held by shareholders including insiders but not including a company's treasury shares assuming conversion of all convertible debt, securities, warrants and options, sourced from the company 10-K or 10-Q SEC reports.
Acrivon Therapeutics, Inc. (ACRV) had Weighted-Average Shares Outstanding (Diluted) of 38.56M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-18.23M |
|
-- |
|
-- |
|
$19.69M |
|
$-19.69M |
|
$1.45M |
|
$-18.23M |
|
$-18.23M |
|
$-18.23M |
|
$-18.23M |
|
$-18.23M |
|
$-18.23M |
|
$-19.69M |
|
$-19.37M |
|
38.56M |
|
|
Weighted-Average Shares Outstanding (Diluted) |
38.56M |
$-0.47 |
|
$-0.47 |
|
| Balance Sheet Financials | |
$130.36M |
|
$5.19M |
|
$14.94M |
|
$145.30M |
|
$14.89M |
|
-- |
|
$1.80M |
|
$16.70M |
|
$128.60M |
|
$128.60M |
|
$128.60M |
|
31.55M |
|
| Cash Flow Statement Financials | |
$-48.43M |
|
$44.58M |
|
$-0.56M |
|
$40.02M |
|
$35.61M |
|
$-4.41M |
|
$11.63M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.75 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-49.88M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-14.18% |
|
-14.18% |
|
-12.55% |
|
-14.18% |
|
$4.08 |
|
$-1.29 |
|
$-1.26 |
|